×
Merck Inventory 2010-2024 | MKKGY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Merck inventory for the quarter ending September 30, 2024 was
$4.844B
, a
10.47% decline
year-over-year.
Merck inventory for 2023 was
$5.019B
, a
2.81% increase
from 2022.
Merck inventory for 2022 was
$4.881B
, a
5.79% increase
from 2021.
Merck inventory for 2021 was
$4.614B
, a
22.63% increase
from 2020.
View More
Merck Inventory 2010-2024 | MKKGY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Merck inventory for 2023 was
$5.019B
, a
2.81% increase
from 2022.
Merck inventory for 2022 was
$4.881B
, a
5.79% increase
from 2021.
Merck inventory for 2021 was
$4.614B
, a
22.63% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$76.8B
Chugai Pharmaceutical (CHGCY)
$66.9B
Takeda Pharmaceutical (TAK)
$42.4B
Sandoz Group AG (SDZNY)
$20.6B
Astellas Pharma (ALPMY)
$17.7B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$16B
Neurocrine Biosciences (NBIX)
$15.3B
Shionogi (SGIOY)
$12.5B
Orion OYJ (ORINY)
$7.5B
Madrigal Pharmaceuticals (MDGL)
$7.1B
Stevanato Group S.p.A (STVN)
$6.5B
Corcept Therapeutics (CORT)
$6.4B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ionis Pharmaceuticals (IONS)
$5.2B
Ono Pharmaceutical (OPHLF)
$4.9B
Grifols, S.A (GRFS)
$4.8B
Crinetics Pharmaceuticals (CRNX)
$3.7B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Recursion Pharmaceuticals (RXRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Centessa Pharmaceuticals (CNTA)
$2.2B
Soleno Therapeutics (SLNO)
$2.1B
Hypermarcas (HYPMY)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.9B
Indivior (INDV)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Evotec AG (EVO)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.4B
ARS Pharmaceuticals (SPRY)
$1.4B